Tongrentang CM's Dendrobium Nobile Powder Receives Approval for Sale in Macau
Stock News
Apr 20
TONGRENTANGCM (03613) announced that its subsidiary, Beijing Tongrentang (Macau) Company Limited, has obtained a Certificate of Registration for Proprietary Chinese Medicine from the Macau Special Administrative Region Government's Pharmaceutical Administration. The approval authorizes the sale of "Dendrobium Nobile Powder [Tongrentang]" in the Macau SAR. The product is indicated for conditions including fluid depletion in febrile diseases, excessive thirst, stomach yin deficiency with poor appetite and dry retching, persistent low-grade fever after illness, yin deficiency with fire hyperactivity, bone-steaming tidal fever, blurred vision, and weak tendons and bones.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.